Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains how Danish patients are benefitting from biosimilars.
Transcript
I think the Danish patients are being impacted in several ways. Firstly, more patients have now access to biological treatment than what they did before; as we all know, biologic medicines have been very, very expensive. They have also been very efficient, but they have been very expensive in Denmark. Last year, of 25 products being used in Danish hospitals, 24 of them were biologics. Of course they have been expensive, but now when you add biosimilars into the market, more patients are being treated, and they're being treated earlier.
At the same time, this would also free up money in other places of the system. We all know we are having a lot of new cancer products coming in. They are, I assume, efficient, but for certain, very expensive.
The fact that you can save a lot of money by using biosimilars will, as I say, free up money that means that other patients, cancer patients, for instance, can benefit because you can start to use new treatment at an earlier point in time without jeopardizing the total health care budget.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.